Latest News | Jubilant Gets VAI Classification from USFDA for Roorkee Unit
Get latest articles and stories on Latest News at LatestLY. Jubilant Pharma on Wednesday said the US health regulator has decided that the inspection classification of its subsidiary's Roorkee-based plant is voluntary action indicated (VAI).
New Delhi, Apr 17 (PTI) Jubilant Pharma on Wednesday said the US health regulator has decided that the inspection classification of its subsidiary's Roorkee-based plant is voluntary action indicated (VAI).
Jubilant Pharmova, a wholly-owned subsidiary of the company, has received a communication from the US Food and Drug Administration (USFDA) that the facility has been classified as VAI pursuant to inspection from January 25 to February 2, 2024, it said in a regulatory filing.
As per the USFDA, a VAI inspection classification indicates that although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time.
"Based on this inspection and the USFDA VAI classification, the facility is considered to be in acceptable state of compliance with regard to current good manufacturing practices (cGMP)," it added.
With this, the FDA has concluded that this inspection is closed, Jubilant Pharma said.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)